Cytokinetics EVP exercises options, sells 4,500 shares

Cytokinetics EVP of Research & Development Fady Malik exercised stock options and sold shares on April 7, 2026.

Accepted by SEC EDGAR 04/08/2026 - 04:18 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Cytokinetics EVP of Research & Development Fady Malik exercised stock options and sold shares on April 7, 2026. He exercised options covering 3,500 shares at $7.80 and 1,000 shares at $10.60 per share, then sold a total of 4,500 common shares in open-market transactions.

The sales involved 3,500 shares at $65.21 and 1,000 shares at $64.75 per share. After these exercise-and-sell transactions, he directly holds 153,902 shares of Cytokinetics common stock. This filing reflects a routine combination of option exercises and partial share sales by a senior executive.

Insider Trade Summary 10b5-1

Exercise and Sale: 4,500 shares ($255K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Malik Fady Ibraham

Role EVP Research & Development

Sold 4,500 shs ($293K)

Approx. gross sale proceeds $293K

Approx. exercise cost $38K

Approx. pre-tax spread $255K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	3,500	$0.00	$0.00
Exercise	Non-Qualified Stock Option (Right to Buy)	1,000	$0.00	$0.00
Exercise	Common Stock	3,500	$7.80	$27K
Sale	Common Stock	3,500	$65.21	$228K
Exercise	Common Stock	1,000	$10.60	$11K
Sale	Common Stock	1,000	$64.75	$65K

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 58,386 contracts (Direct); Common Stock — 153,902 shares (Direct)

Key Figures

Options exercised (7.80): 3,500 shares Options exercised (10.60): 1,000 shares Shares sold (higher price): 3,500 shares at $65.21 +4 more

7 metrics

Options exercised (7.80) 3,500 shares Non-qualified stock option exercise at $7.80 per share on April 7, 2026

Options exercised (10.60) 1,000 shares Non-qualified stock option exercise at $10.60 per share on April 7, 2026

Shares sold (higher price) 3,500 shares at $65.21 Open-market sale of common stock on April 7, 2026

Shares sold (second trade) 1,000 shares at $64.75 Open-market sale of common stock on April 7, 2026

Total shares sold 4,500 shares Net disposition in this Form 4, combining two sales

Post-transaction holdings 153,902 shares Common stock directly owned after April 7, 2026 transactions

Exercise price (options) $7.80 and $10.60 Strike prices for the exercised non-qualified stock options

Key Terms

Non-Qualified Stock Option (Right to Buy), open-market sale, derivative security, exercise price

4 terms

Non-Qualified Stock Option (Right to Buy) financial

"Security titled "Non-Qualified Stock Option (Right to Buy)" was exercised for common stock."

open-market sale financial

"The Form 4 lists an open-market sale of common stock at $65.21 per share."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative security financial

"The option exercise is described as an "Exercise or conversion of derivative security"."

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

exercise price financial

"Each option transaction specifies an exercise price of $7.80 or $10.60 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cytokinetics (CYTK) EVP Fady Malik report?

He reported exercising stock options and selling common shares. Malik exercised options for 4,500 shares, then sold those 4,500 Cytokinetics common shares in open-market transactions on April 7, 2026, while remaining a substantial shareholder after the trades.

How many Cytokinetics (CYTK) shares did EVP Fady Malik sell?

He sold a total of 4,500 Cytokinetics common shares. The transactions comprised 3,500 shares sold at $65.21 per share and 1,000 shares sold at $64.75 per share, following the exercise of corresponding stock options on the same date.

At what prices did Cytokinetics (CYTK) EVP Fady Malik exercise his options and sell shares?

He exercised options at $7.80 and $10.60 per share, then sold shares at much higher prices. Specifically, 3,500 shares were sold at $65.21 and 1,000 shares at $64.75, illustrating an exercise-and-sell pattern common for monetizing stock-based compensation.

How many Cytokinetics (CYTK) shares does EVP Fady Malik hold after these transactions?

After the reported transactions, he directly holds 153,902 Cytokinetics common shares. This figure reflects his position after exercising stock options for 4,500 shares and selling those 4,500 shares in open-market trades on April 7, 2026.

What type of securities did Cytokinetics (CYTK) EVP Fady Malik exercise in this Form 4 filing?

He exercised non-qualified stock options, which are rights to buy common shares at preset exercise prices. The options covered 3,500 shares at $7.80 and 1,000 shares at $10.60, converting option awards into common stock before the related sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malik Fady Ibraham

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Research & Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/07/2026		M		3,500	A	$7.8	157,402	D
Common Stock	04/07/2026		S		3,500	D	$65.21	153,902	D
Common Stock	04/07/2026		M		1,000	A	$10.6	154,902	D
Common Stock	04/07/2026		S		1,000	D	$64.75	153,902	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$7.8	04/07/2026		M			3,500	03/27/2018	02/27/2028	Common Stock	3,500	$0	58,386	D
Non-Qualified Stock Option (Right to Buy)	$10.6	04/07/2026		M			1,000	03/28/2017	02/28/2027	Common Stock	1,000	$0	0	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Dr. Malik	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)